Literature DB >> 9697749

Selective increase in plasma tumor necrosis factor-alpha and concomitant clinical deterioration after initiating therapy in patients with severe tuberculosis.

L G Bekker1, G Maartens, L Steyn, G Kaplan.   

Abstract

The initiation of antituberculosis treatment in patients with severe tuberculosis may be accompanied by clinical deterioration and even death before any improvement occurs. To investigate this phenomenon, newly diagnosed human immunodeficiency virus-negative adults with severe tuberculosis were followed for the first 42 days of standard short-course therapy. Clinical status, serum lactate, plasma cytokine, and plasma cytokine receptor levels were monitored on days 0, 3, and 7 and then weekly for up to 42 days. Following 7 days of antituberculosis therapy, a significant transient decrease in mean Karnofsky score (P < .001), a concomitant increase in serum lactate (P = .06), a decrease in patient weight (P = .02), and an increase in plasma tumor necrosis factor-alpha (TNF-alpha) concentrations (P = .04) were observed. Plasma levels of soluble interleukin-2 receptor, interferon-gamma, interleukin-6, and TNF-alpha receptor decreased over the 42-day study period. These observations suggest that increases in plasma TNF-alpha levels may be associated with clinical deterioration observed early in the treatment of severe tuberculosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9697749     DOI: 10.1086/517479

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  41 in total

Review 1.  Serological markers of disease activity in tuberculosis and HIV infection.

Authors:  A Marchant
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

2.  Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment.

Authors:  Stephanie L Davis; Eric L Nuermberger; Peter K Um; Camille Vidal; Bruno Jedynak; Martin G Pomper; William R Bishai; Sanjay K Jain
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

3.  Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology.

Authors:  Selvakumar Subbian; Liana Tsenova; Paul O'Brien; Guibin Yang; Mi-Sun Koo; Blas Peixoto; Dorothy Fallows; Jerome B Zeldis; George Muller; Gilla Kaplan
Journal:  Am J Pathol       Date:  2011-05-07       Impact factor: 4.307

Review 4.  Latent tuberculosis infection: myths, models, and molecular mechanisms.

Authors:  Noton K Dutta; Petros C Karakousis
Journal:  Microbiol Mol Biol Rev       Date:  2014-09       Impact factor: 11.056

5.  Recombinant guinea pig tumor necrosis factor alpha stimulates the expression of interleukin-12 and the inhibition of Mycobacterium tuberculosis growth in macrophages.

Authors:  Hyosun Cho; Todd M Lasco; Shannon Sedberry Allen; Teizo Yoshimura; David N McMurray
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

6.  Pentoxifylline treatment of mice with chronic pulmonary tuberculosis accelerates the development of destructive pathology.

Authors:  J Turner; A A Frank; J V Brooks; P M Marietta; I M Orme
Journal:  Immunology       Date:  2001-02       Impact factor: 7.397

7.  Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda.

Authors:  C C Whalen; P Nsubuga; A Okwera; J L Johnson; D L Hom; N L Michael; R D Mugerwa; J J Ellner
Journal:  AIDS       Date:  2000-06-16       Impact factor: 4.177

8.  A study of serum malondialdehyde and cytokine in tuberculosis patients.

Authors:  Rashmi Kulkarni; Ajit Deshpande; Ravi Saxena; Kiran Saxena
Journal:  J Clin Diagn Res       Date:  2013-10-05

Review 9.  Novel adjunctive therapies for the treatment of tuberculosis.

Authors:  A A Ordonez; M Maiga; S Gupta; E A Weinstein; W R Bishai; S K Jain
Journal:  Curr Mol Med       Date:  2014-03       Impact factor: 2.222

10.  Inflammatory responses in blood samples of human immunodeficiency virus-infected patients with pulmonary infections.

Authors:  Natividad Benito; Asunción Moreno; Xavier Filella; José M Miró; Julià González; Tomás Pumarola; María Eugenia Valls; Montserrat Luna; Felipe García; Ana Rañó; Antoni Torres; José M Gatell
Journal:  Clin Diagn Lab Immunol       Date:  2004-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.